Composition
Olosol Eye Drops: Each ml sterile eye drop contains Olopatadine Hydrochloride USP equivalent to Olopatadine 1 mg.
Preservative: Benzalkonium Chloride BP 0.02%
Pharmacology
Olopatadine inhibits the release of histamine from the mast cell & is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells. Olopatadine has no effects on alpha-adrenergic, dopamine and muscarinic type 1 & 2 receptors.
Indication
Olopatadine eye drops is indicated for the treatment of signs and symptoms (itchy, watery, red and swollen eyes or eyelids) of allergic conjunctivitis including vernal keratoconjunctivitis, blepharoconjunctivitis and giant papillary conjunctivitis.
Dosage & Administration
Olosol Eye Drops: The recommended dose is 1 drop in the affected eyes two times daily.
or, as directed by the registered physician.
Contraindication
Olopatadine Hydrochloride is contraindicated in persons with a known hypersensitivity to any component of this product.
Warning & Precaution
Patients should be advised not to wear a contact lens if their eye is red. Olopatadine ophthalmic solution should not be used to treat contact lens related irritation. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least 10 minutes after instillation of Olopatadine ophthalmic eye drops before they insert their contact lenses. The treatment should be discontinued in the presence of an allergic reaction.
Side Effects
Rarely headaches have been reported. Other adverse effects: asthenia, blurred vision, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, nausea, pharyngitis, pruritus, rhinitis, sinusitis, and taste perversion.
Use in Pregnancy and Lactation
Olopatadine was not found to be teratogenic in rats and rabbits. However, there are no adequate and well controlled studies in pregnant women. This drug should be used in pregnant women only if the potential benefit justifies the potential risk to the fetus. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Nevertheless, caution should be exercised when Olopatadine is administered to a nursing mother.
Drug Interaction
Specific drug interaction studies have not been conducted with Olopatadine ophthalmic solution.
Overdose
There is no information on Olopatadine overdose. However, excessive use of any medication can have serious consequences. If you suspect an overdose, seek medical attention without delay.
Storage
Store below 25°C, Protect from light and moisture. Keep out of the reach of the children.
Note: Do not use longer than 30 days after first opening.
Packaging
Olosol Eye Drops: Each dropper bottle contains 5 ml sterile eye drops.
